Therapy with Bone-Seeking Radiopharmaceuticals in Patients with Skeletal Metastases Beyond Simple Palliation of Bone Pain

Summary

Bone metastases account for most of the morbidity and deterioration in the quality of life experienced by patients with various types of solid cancers, and occur in about 65–70% of the cases with advanced breast or prostate cancer. Clinical management of metastatic bone pain includes several options (1, 2) to be employed either alone or in varying combinations. One step further in this direction is a multicenter trial exploring the anti-tumour therapeutic potential of the association between ¹⁵³Sm-EDTMP (Quadramet^®) and Docetaxel in patients with hormone-refractory prostate cancer with predominant bone metastases.

• References

• 1 Cleeland CS, Gonin R, Hatfield AK. et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-596
• 2 Coleman RE. Management of bone metastases. The Oncologist 2000; 5: 463-470.
• 3 Krishnamurthy GT, Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med 2000; 41: 688-691.
• 4 Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46: 38S-47S.
• 5 Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40: 89-104.
• 6 McQuay HJ, Collins S, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2000; CD001793.
• 7 Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109: 637-643.
• 8 Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F. EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008; 35: 1934-1940.
• 9 Tu S-M, Millikan RE, Mengistu B. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001; 357: 336-341.
• 10 Ricci S, Boni G, Pastina I. et al. Clinical benefit of bone-targeted radiometabolic therapy with ¹⁵³Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1023-1030.
• 11 Amato RJ, Hernandez-McClain J, Henary H. Bonetargeted therapy phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol 2008; 31: 532-538.
• 12 Fizazi K, Beuzeboc P, Lumbroso J. et al. Phase II trial of consolidation Docetaxel and Samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2429-2435.
• 13 Tu SM, Mathew P, Wong FC, Johnson MM, Logothetis CJ. Phase I Study of concurrent weekly Docetaxel and repeated Samarium-153 Lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncology 2009; 27: 3319-3324.